Ngā hua rapu - Adalbert Weißmann
- E whakaatu ana i te 1 - 2 hua o te 2
-
1
Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis mā Matthias Pinter, Wolfgang Sieghart, Ivo Graziadei, Wolfgang Vogel, A Maieron, Robert Königsberg, Adalbert Weißmann, Gabriela Kornek, Christina Plank, Markus Peck‐Radosavljevic
I whakaputaina 2009Artigo -
2
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma mā Heinz Ludwig, H. Kasparu, Clemens Leitgeb, Elisabeth Rauch, Werner Linkesch, Niklas Zojer, Richard Greil, Adelheid Seebacher, Luděk Pour, Adalbert Weißmann, Zdeněk Adam
I whakaputaina 2013Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Gastroenterology
Internal medicine
Medicine
Bendamustine
Bortezomib
Chemotherapy
Cirrhosis
Dexamethasone
Disease
Hepatocellular carcinoma
Lenalidomide
Liver cancer
Liver function
Lymphoma
Multiple myeloma
Multivariate analysis
Oncology
Progressive disease
Regimen
Rituximab
Salvage therapy
Sorafenib
Surgery
Thalidomide
Univariate analysis